Want to see PGNY full AI Analyst Report?
Revenue by Segment
Breaks revenue into customer types or service lines, revealing which segments drive growth, where margins differ, and potential concentration or diversification risks that affect future earnings stability.Progyny’s top-line is increasingly driven by Fertility Benefit Solutions, which shows steady, seasonally amplified expansion and now dominates growth—turning the company into a more single-product growth story. Pharmacy Services delivered a dramatic earlier ramp but has flattened/softened in the past year, suggesting prior gains may have been transaction- or integration-driven and are normalizing. For investors, future upside hinges on sustaining FBS utilization and pricing; Pharmacy Services now looks less reliable as a growth diversifier and a potential limit on overall revenue momentum.
Date | Fertility Benefit Solutions | Pharmacy Services |
|---|---|---|
Jun 30, 2026 | $230.20M | $120.30M |
Mar 31, 2026 | $209.40M | $119.10M |
Dec 31, 2025 | $208.68M | $109.83M |
Sep 30, 2025 | $201.95M | $111.40M |
Jun 30, 2025 | $213.90M | $118.90M |
Mar 31, 2025 | $206.40M | $117.60M |
Dec 31, 2024 | $187.50M | $111.00M |
Sep 30, 2024 | $178.80M | $107.90M |
Jun 30, 2024 | $193.60M | $110.50M |
Mar 31, 2024 | $169.80M | $108.30M |